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Abstract 
 Background: The leishmaniasis are a group of diseases caused by protozoan parasites of the 
genus Leishmania.  Leishmania are, obligate intracellular kinetoplastid protozoan parasites, that 
are transmitted through the bite of a vector called sandy fly. The disease ranges from self-healing 
cutaneous to visceral leishmaniasis (VL), which is severe and can causes death when untreated.  
Following the delivery of parasites by sand fly bite or by needle injection, neutrophils have been 
found the first recruited to the infection site. The role of neutrophils in either promoting or 
suppressing host immune response remains controversial. 
Objective: To assess the effect of EDTA and heparin anticoagulants on the survival of LDGs in 
PBMCs and the release of interferon-γ and IL-10 in the WBA. 
Methods: A cross-sectional study was conducted on clinically and laboratory confirmed VL 
patients from December 2014 to May 2015 at University of Gondar Hospital. Convenience 
sampling technique was used to select study participants and all consecutive VL cases who came 
to the hospital during the study period and controls were included. 6 ml of blood using EDTA 
and 6 ml using heparin was collected from all study participants before and after treatment  and 
from controls to assess the effect on LDGs using FACs caliber, arginase activity using 
Enzymatic assay and production of IFN-γ and IL-10 using ELISA. Data were evaluated using 
GraphPad Prism 6 and differences were considered statistically significant at p < 0.05. FACS 
data were analyzed using Summit v4.3 software. 
Results: The frequency of LDGs is significantly lower when the blood is collected with heparin 
as compared to EDTA. Anticoagulants does not have an impact on the levels of arginase 
released. And results show that EDTA prevents the production of IFN-γ. Cells from active VL 
patents produce no or low levels of IFN-γ and IL-10, however, after successful treatment, these 
cells gradually regain their capacity to produce IFN-γ, but not IL-10. 
Conclusion and recommendations: In this study results suggest that, VL patients have lost their 
ability to mount a Th1 response during active VL and that active disease is not associated with 
sustained levels of IL-10. For the future in vitro experiment, choosing different anticoagulants to 
study about different cells and T cell response against leishmania is important.  
 
Key Words:-  Leishmania, Neutrophil, Heparin, EDTA, IFN - gamma 
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1.  Introduction  
1.1  Background  
The leishmaniasis are a group of diseases caused by protozoan parasites of the genus 
Leishmania.  Leishmania are, obligate intracellular kinetoplastid protozoan parasites that are 
transmitted through the bite of a vector called sandy fly. The disease ranges from self-healing 
cutaneous to visceral leishmaniasis (VL), which is severe and can causes death when untreated 
(1).  
Globally, endemic leishmaniasis was reported in a total of 98 countries. The reported cases of   
cutaneous leishmaniasis per year was more than 220,000 (2). 
Visceral leishmaniasis is fatal disease if left untreated. Estimated annual global incidence of VL  
is 200,000–400,000 and more than 90% of cases occur in countries like Sudan, India, 
Bangladesh, South Sudan, Brazil and Ethiopia (2). 
In Ethiopia, VL is caused by L. donovani and it is one of the most significant vector-borne 
diseases; Ethiopia has the second largest number of VL cases in sub-Saharan Africa with an 
estimated annual burden of 4500 to 5000 new cases (3).   
There are different forms of cutaneous leishmaniasis. Such as Localized cutaneous leishmaniasis 
(LCL), Mucocutaneous Leishmaniasis (MCL) and Disseminated cutaneous leishmaniasis (DCL)  
LCL heals spontaneously but it can take months to years to heal and varies depending on the 
species (4). MCL is a type of leishmaniasis which is chronic, caused by L. braziliensis, L. 
panamensis,, L. guyanensis and L. amazonensis, typically seen in central and South America. 
and  may spread to mucosal membrane, particularly to the throat, mouth and nose and can cause 
extensive damage that leads to disfiguration (5).  
Visceral leishmaniasis or kala-azar is usually caused by L. donovani and L. infantum, and the 
disease is characterized by splenomegaly, weight loss, progressive fever, 
hypergammaglobulinemia, pancytopenia and hepatomegaly (6) and VL also causes different 
complications like immunosuppression and secondary bacterial infections, hemorrhage and 
anemia (7). 
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Because leishmania are obligate intracellular parasites, the humoral immune response is not 
effective and cell mediated immunity is required for control of infections caused by all 
leishmania species (8). 
 
In experimental model, immune responses that are mediated by T-cell play a central role in the 
processes of either cure or aggravation of the disease. Resistance to Leishmania infection 
depends on polarization of the immune response towards T-helper-1 type which induces 
production of IL-12 and IFN-γ, while disease progression is related to development of T-heper-2 
type of immune response in which IL-4 and IL-5 have a significant contribution (9). 
Following the delivery of parasites by sand fly bite or by needle injection, neutrophils have been 
found the first recruited to the infection site (10). 
The best-characterized function of neutrophils or polymorphonuclear neutrophils is their role in 
the phagocytosis and killing of invading microorganisms via the generation of oxygen 
intermediates and the lytic enzymes released from their granule (11). 
 
Neutrophils also takes part during inflammation process which is an important step to combat 
pathogens at early phase of infection. Furthermore, an immune regulatory role of neutrophil has 
been identified via the secretion of cytokines and chemokines. This role is additional to their 
being key component of inflammatory response (12),  Neutrophils are shown to contribute to the 
recruitment and activation of antigen-presenting cells (APCs) (13). Thus, neutrophils are now 
recognized as important decision shapers during the early phases of the immune response (11). 
 
Neutrophils are short-lived leukocytes that die by apoptosis, necrosis, and Neutrophil 
Extracellular Traps (NETosis). However, following infection, their lifespan can be increased to 
several days (14). 
Upon death by NETosis, neutrophils release fibrous traps of deoxyribosenucleic acid (DNA), 
histones, and granule proteins named NETs, which can kill bacteria and fungi. Studies done with 
leismania amazonensis show the release of NETs by human neutrophils upon their interaction 
with leishmania parasites. Leishmania and the lipophosphoglycan expressed on the parasite 
surface induced NET release by neutrophils, important for killing of the parasite (15).  
3 
 
Based on the expression of CD28 surface markers Polymorphoneuclear neutrophils can be 
divided into either CD28+ or CD28- cells on the basis of their capacity to express CD28. CD28+ 
and CD28- neutrophils phagocytose Leishmania parasites and secret Interleukin-8 that amplifies 
the neutrophils at the site of infection (16). 
About 47% human peripheral blood neutrophils express CD28 and that CD28 signals through 
IP3 kinase will induces IFN-γ and T cell chemotactic factor, suggesting the role of neutrophils in 
initiation of T cell response against leishmania (17). 
Leishmania parasites exist in two distinct morphological forms in mammalian host promastigote 
and Amastigote. The motile flagellated promastigote exist, multiply and develop extera cellularly 
in the alimentary tract of the female sand fly vector (18). During the blood meal Promastigotes 
are phagocytosed by macrophages or neutrophils (19). In vacuolar compartments of macrophage 
Promastigotes will differentiate to another stage called amastigote. Amastigotes multiply by 
binary cell division and can spread to other phagocytic cells like dendritic cells (DC) and other 
macrophages (20). 
Given that, leismaniasis is a main public health problem, finding new and effective control 
measures are commendable. Control of leishmaniasis usually depends on case detection, 
treatment, vector and reservoir control. Early detection of the disease and treatment are essential 
for individual patients and also for the community. If VL patients are treated in an early stage, 
the outcome of the treatment will be better. VL patients that are not treated can act as a source of 
infection and then contribute to disease transmission (21,22). 
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1.2  Statement of the problem 
Neutrophils are readily mobilized innate immune cells and are essential for host defense   
mechanism against different pathogens (23). Evidence is emerging that PMN can play a part in 
antigen presentation, and as a result this could have an impact on the induction and the quality of 
the T-cell response (24). 
The role of neutrophils in either promoting or suppressing host immune response remains 
controversial. Data indicates that PMN can also have immunosuppressive functions. 
Polymorhoneuclar neutrophils are having different effector functions during pathogen invasion. 
The first is through  L-arginine metabolizing enzymes, arginase and nitric oxide synthase (NOS), 
and the second is using phagocytosis-associated oxidases (PHOX) that produce reactive oxygen 
species (ROS). Both ROS (25) and nitrogen intermediates (26) have the ability to inhibit T cell 
activation. 
Arginase is the enzyme that hydrolyzes arginine and catalyzes the hydrolysis of L-arginine to 
urea and ornithine. Arginase I and II are the two isoforms of the enzyme arginase. Arginase I is a 
trimeric cytosolic protein and is expressed in erythrocytes in humans and higher primates. 
Arginase II, which is the second isoform, is also a trimeric mitochondrial protein, and is 
expressed in extrahepatic tissues like brain, kidney, small intestine, macrophages and monocytes 
(27). Arginase II is synthesized as a pre-protein, and processed to the mature form after imported 
to mitochondria (28). 
Efficient activation of T cells is depending on the availability of L-arginine and has been shown 
to be inhibited when extracellular L-arginine is depleted (26,29). Human PMN constitutively 
express high amounts of arginase I, which is contained within their azurophilic granules (30). 
Arginase release from PMN either by active degranulation or by their death leads to depletion of 
extracellular L-arginine, and profound suppression of T cell activation (31). 
Anticoagulants are commonly used for blood collection activity and heparin has a well-known 
anticoagulant, and is a member of the family of polysaccharides, the glycosaminoglycans 
(GAGs) (32). Furthermore, independent of anticoagulant activities many of the anti-
inflammatory activities of heparin are now known (33). Heparin has been shown to modify many 
other aspects of inflammatory processes involving neutrophils. For example, heparin has the 
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ability to inhibit the binding of IL-8 to neutrophils (34), neutrophil degranulation and the 
respiratory burst is also inhibited by heparin (35). 
Ethylene Diamine TetraAcetic Acid (EDTA) is another anticoagulant currently recommended for  
routine full blood cell counts (36). The effect of anticoagulants on  
the isolation of human neutrophils was assessed and have shown that EDTA provided the highest 
number of isolated neutrophils /ml of blood compared with heparin (37). 
 
In normal peripheral blood mononuclear cells (PBMCs) isolation, neutrophils co-purify in the 
erythrocyte fraction and not within PBMCs when blood is collected using tube containing of 
EDTA. However, arginase-expressing CD15+ cells also co-purify in the PBMC fraction, and 
because of their difference in density, this population is named low-density granulocytes 
(LDGs). The frequency of LDGs was significantly higher in the PBMCs of active VL patients. 
After getting treatment, the frequency of LDGs was considerably lower (38). PBMCs from 
active VL patients are characterized by their inability to elicit an immune response, as shown by 
impaired proliferation and production of IFN-γ (39,40). 
Based on extensive studies done in L. major infected inbred strains of mice, healing of disease 
and host defense against Leishmania infection is mainly depend on the development of a Th-1 
type response, characterized by the production of IFN-γ and non-healing is associated with Th-2 
type of immune response dominated by the production of IL-4 (8). 
A recent publication showed unexpected results; they found that there was production of IFN-γ 
in patients with active VL upon stimulation with Leishmania antigen in the whole blood assay, 
by using tubes containing heparin to draw venous blood and conclude that all antigens tested 
showed positive IFN-γ responses in active VL with highest value (41).  
Moreover, another study has shown that immune responses against the infection in active VL 
patients are suppressed and PBMCs don’t proliferate and produce IFN-γ in response to 
Leishmania antigen  (42). 
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1.3 Rational of the study 
A remarkable effect of heparin on the survival of LDGs has been shown, a dramatic decrease in 
the frequencies of LDGs was observed when the blood was collected into heparin tubes as 
compared to EDTA (43). Given that in the studies that showed IFN- γ production by VL patients 
whole blood assay was used and, blood was collected into heparin anticoagulant, it is possible 
that the resulting low frequency of LDGs was not sufficient to suppress the production of IFN-γ 
(44). Thus, the hypothesize was the use of heparin as an anticoagulant in the whole blood assay 
reduced the survival of LDGs and thereby affect T- cell response.  
There is no study previously conducted to assess the effect of anticoagulants on the survival of 
activated, low density neutrophil (LDGs) in visceral leishmaniasis and how this may affect T cell 
responses. Therefore, this study intended to generate information about the effect of 
anticoagulants on the frequency of LDG and the release of IFN-γ and IL-10 before and after 
treatment. So that for the future in vitro experiments, researchers will use the correct 
anticoagulant to study T-cell responses against Leishmania antigen and to avoid ambiguous 
patient results.  
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2. Literature review 
For quite some time, it has been thought that based on studies done in murine L. major models in 
mouse, there is a shift in immune response and it will be dominated by Th2 immune response, 
which is characterized by the release of IL-4 and IL-5, favors for parasite survival. This will lead 
to the impairment of CD4+ Th1-cells to produce INF- γ, which is important for activation of 
macrophages and DCs that leads to parasite death (8,10). 
Conversely other studies have shown that there is no a clear Th2 skewing in human VL.  During 
acute phase of infection, high level of IFN-γ detected in blood serum, and elevated levels of 
IFNγ mRNA has been found in lymphoid organs like spleen and bone marrow. These 
observations suggest that the immune system is highly activated and the development of VL is 
not determined by Th2 skewing but other mechanisms may contribute for pathogenesis of VL  
(40). 
As well, study performed in India assessed the production of IFN-γ in whole blood from active 
VL patients by using Interferon gamma release assay (IGRA). An increased production of IFN-γ 
reported when stimulated with Soluble Leishmania antigen (SLA) in 80% (28/35) patients with 
no difference in the mean level of IFN-γ compared to cured VL (45). 
In addition to this, unexpected findings were reported in a study that have used whole blood 
Interferon-γ release assay using a modified technique called modified QuantiFERON, which is a 
potential marker of L. donovani infection and there was production of IFN-γ after stimulation 
with SLA 85% (11/13) patients with active VL (41). 
Furthermore, studies in India have shown significantly higher levels of circulating IFN-γ and IL-
10  in VL samples before treatment as compared to post treatment of VL (44). Other studies also 
showed similar results using serum samples from Sicilian patients with confirmed VL and 
controls. There was a significant increase in the serum concentration of IFN-γ in patients with 
active VL, compared to controls and returned to normal after recovery (46). 
An epidemiological study of visceral leishmaniasis (VL) conducted in south-west Ethiopia, with 
a group of 109 subjects including healthy controls were studied for T cell subsets and cytokine 
profiles, the plasma concentrations of both IFN-γ and IL-10 were significantly higher in patients 
with active VL, when compared to controls (47). 
8 
 
Over all the above studies have shown that there is an increased production of IFN-γ in whole 
blood assay after activation with SLA and also in sera or plasma of patients with active VL. This 
could be the effect of heparin on the survival of LDGs and these cells will not be sufficient to 
suppress IFN-γ  production by T-cell (43). 
Furthermore, different studies showed activation of the T cell is depend on the availability of L-
arginine. During degranulation, PMNs release arginase and this  result depletion of extracellular 
L-arginine and thus T-cell activation become suppressed and unable to produce IFN-γ (29-31).  
Studies done in Gondar, Ethiopia shows contradictory idea from the above studies because they 
identified the phenotype of arginase-expressing cells among PBMCs as neutrophils (known as 
LDGs) shows that their frequency was increased in PBMCs of patients before treatment by using 
EDTA as an anticoagulant. This coincides with reduced levels of L-arginine in the plasma and 
decreased expression levels of T cell receptor ζ chain (CD3ζ) in T cells, principal signal 
transduction element of the T cell antigen receptor (TCR), which is important for T cell 
activation. Significantly lower CD3ζ in CD4+ T cells from patients with active VL before 
treatment was observed when compared to controls and treated patients which shows a higher 
CD3 ζ in CD4+ T cells (38,48). The authors hypothesized that this results in T cell suppression 
and impaired capacity to proliferate and produce IFN-γ (49). 
The above discrepancy between studies may came from anticoagulants they used, one used 
heparin and the other EDTA. Here in the present study shows the impact of EDTA and Heparin 
on the frequency of LDGs, and activation of T cells in patients with active VL before and after 
treatment. 
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2. Objective 
2.1 General Objective 
 To assess the effect of EDTA and Heparin anticoagulants on the survival of LDGs in PBMCs 
and the release of interferon-γ and IL-10 in the WBA 
 
2.2 Specific Objective 
 To determine the effect of EDTA and heparin on the frequency of LDGs in PBMCs from 
untreated patients with active VL 
 To determine arginase activity in EDTA and heparin following antigen-specific and 
polyclonal simulation in WBA  
 To determine the effect of heparin and EDTA on antigen-specific and polyclonal T cells 
activation in WBA in VL patients before and after treatment 
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3. Materials and Methods 
3.1 Study Design 
 A cross-sectional study was used  
 3.2  Study Setting and period 
The study was conducted from December 2014 to May 2015 at University of Gondar Hospital 
and Gondar is found in Amhara region of North west Ethiopia and is around 740 km far from 
capital city of Ethiopia which has an average population of 300,000 and it has an average altitude 
of 2160 above sea level, Gondar University Hospital is found in Gondar town and give different 
health service for the community and it has different research centers.   
3.3  Populations 
3.3.1  Target population 
All patients suspected for visceral leishmaniasis who attended Gondar University Hospital 
during the study period 
3.3.2  Study population 
All VL confirmed patients who visited  Gondar University Hospital during the study period. 
3.3.3  Inclusion Criteria 
All clinically and laboratory confirmed VL patients and Willingness to take part in the study 
3.3.4  Exclusion Criteria 
- HIV- coinfection  
- Age less than 18 years 
- TB - coinfection 
- Malaria-coinfection 
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3.4 Sampling technique and Sample size  
Convenient sampling technique was used. All consecutive clinically and laboratory confirmed a 
total of  69 VL patients who came to Gondar University Hospital during the study period and 10 
controls were included in the study.  
 3.5 Study Variables 
3.5.1 Dependent variables 
 Frequency of LDGs 
      Arginase activity 
    Production of  IFN- γ and IL-10  
3.5.2 Independent variables 
 EDTA, Heparin   
3.6 Sample collection and procedures  
A total of 12 ml of blood sample was collected in EDTA and heparin tubes at baseline before 
leishmania treatment and also after treatment. Two ml with SLA, 2ml with PHA and 2ml with nil 
stimulated samples were collected to determine frequency of LDGs, Arginase activity and 
production of IFN-γ and IL-10. 
3.6.1 Laboratory Evaluation  
HIV was screened following the national algorithm with the following tests : KHB (Shanghai 
Kehua Bio-engineering Co. Ltd), HIV ½ STAT- PAK (Chembio) and Uni-Gold (Trinity Biotech 
PLC). Haematology analysis (platelet counts, white blood cell counts, hematocrit and 
haemoglobin) were done  with a COULTER AcT diff Hematology Analyzer. 
3.6.2 Flow Cytometry 
Flow cytometry was done using FACS (Flouresent Activated Cell Sorter) Calibur (BD 
Biosciences) to assess the frequency (% histogram) of LDGs. 
Flow cytometry uses the principles of light scattering, light excitation, and emission of 
fluorochrome molecules to generate specific multi-parameter data from particles and cells 
according to their size and uses the principle of hydrodynamic  focusing for presenting cells to a 
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laser. cells were differentiated by using forward and sideward scatter and monoclonal antibodies 
labeled with florochrome were bind with the specific cell surface marker.  
Antibodies were used as follows: anti-CD15 (Clone H198, BD Pharmingen) labeled with 
Phycoerythrin (PE) florochrome and Anti-arginase I (HyCult Biotechnology: clone 6G3) labeled 
with Fluorescein Isothiocyanate (FITC) florchrome. Cells were washed with PBS, the fixation 
step was performed with 2% formaldehyde in PBS and the permeabilization step ( intracellular 
staining for Arginase) was with 0.5% saponin in PBS and data were analyzed using Summit v4.3 
software. 
3.6.3 Determination of arginase activity 
To activate arginase, 50μl of PBMCs (resuspended in lysis buffer = 0.1% Triton X-100/10 mM 
MnCl2/ 25 mM Tris-HCl) were incubated for 7 min at 56
0
C. Arginine hydrolysis was achieved 
by incubating the lysate with 50 μl of 0.5 M L-arginine (pH 9.7) at 370C for 120 min. The 
reaction was stopped with 400μl of H2SO4 (96%)/H3PO4 (85%)/H2O (1/ 3/7, v/v/v). Urea 
concentration was measured at 540 nm after addition of 20 μl a-isonitrosopropiophenone 
(dissolved in 100% ethanol), followed by heating at 100
0
C for 45 min. To determine arginase 
activity in the plasma (supernatant from stimulated cells), urea concentrations were first 
determined in the plasma, without the activation and hydrolysis steps; these values were 
subtracted from those obtained by measuring the urea levels as described above. One unit of 
enzyme activity is defined as the amount of enzyme that catalyzes the formation of 1 mmol of 
urea per min. 
3.6.4 Antigens (SLA) 
Soluble Leishmania  antigen (SLA) was prepared from stationary-phase Leishmania donovani 
promastigotes, harvested after the third or fourth passage. Parasites were washed in 
15mM  phosphate-buffered saline (PBS), pH 7.4, and the pellet ressuspended at a concentration 
of1×10
8
  cells/ml in 15mM  PBS, pH 7.4. The suspension was rapidly frozen at 70
o
C and thawed 
at 37
o
C, three times and sonicated between each step. After sonication, the lysate was 
centrifuged (37000g ) for 90 min, the supernatant collected, dialyzed overnight against 
15mM  PBS, pH 7.4, sterilized by filtration through 0.22-mm-pore-size membrane (Filter millex, 
Milipore Products Division, Bedford, MA, USA) and stored at 70
o
C until use. 
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Phytohaemagglutinin (PHA) and Phosphate buffered saline (PBS) were used as positive and 
negative controls, respectively. 
3.6.5 Collection of blood and stimulation of cells 
Two ml of blood was collected in EDTA and 2ml in Heparin containing tubes. Blood collected 
in the presence of the different anticoagulants was tested for their ability to respond to antigenic 
stimulation using 5μg/mL of the SLA antigen described above and in each test 10 μg/mL PHA 
was used as a positive control and unstimulated cells (nil, PBS) were used as negative controls 
After adding antigens (75μl of SLA for 2ml of blood) and mitogens (20μl of PHA for 2 ml of 
blood) and PBS (75μl) to the not stimulated group, all tubes were thoroughly mixed.  All  atubes 
were incubated upright in a 37
0
C incubator for 24 hrs without humidity and CO2. After 
incubation and centrifugation at 10,000rpm for 5 min, supernatant plasma were collected and 
stored at -20
o
C for IFN-γ and IL-10 analysis. 
3.6.6 Measurement of  Interferon-gamma and Interleukin -10 by ELISA 
 
The level of IFN-γ and IL-10 secreted by cells stimulated in the WBA was measured using 
Human IFN-γ and IL-10 ELISA Ready-SET-Go! kit using manufacturer’s instructions. A 
standard curve with 8 serial dilutions of known amounts of recombinant human IFN-γ (in 
picograms per milliliter (pg/ml)) was done in each test and used to determine the levels of IFN-γ 
produced in response to specific stimulation with Leishmania antigens, in response to mitogens 
and to determine the spontaneous release in the nonstimulated control group.  Microtiterwells 
without any test sample but all contents of the ELISA were used to determine the background of 
the ELISA assay. The IL-10 content of all samples was also tested by ELISA following the same 
protocol as described for IFN-γ. Antigen-specific IFN-γ and IL-10 levels (expressed in pg/mL) 
produced in response to SLA stimulation were determined by subtracting background levels 
measured in the unstimulated nil (PBS) samples. The mitogen-induced IFN-γ and IL-10 levels 
(expressed in pg/mL) produced in response to PHA stimulation were determined by subtracting 
background levels measured in the unstimulated nil (PBS) samples. 
The detection limit for IFN-γ was 4 pg/ml with the standard curve ranging from 4-500pg/ml ( 
considered as positive IFN γ production), the low detection limit was < 4pg/ml and the upper 
detection limit and > 500pg/ml. If a test sample was above the high detection limit, the sample 
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was diluted and the assay repeated to obtain values that fit into the detection limits of the assay 
and the for the calculation of the cytokine levels in the diluted samples, values measured were 
multiplied by the dilution factor. 
The detection limit for IL-10 was 2 pg/ml and the standard curve ranged from 2-300 pg/ml 
(considered as positive IL-10 production), the low detection limit was < 2 pg/ml and > 300pg/ml 
was the high detection limit.. 
3.6.7  Data Processing and Analysis 
Data were evaluated for statistical differences using a two-tailed Mann-Whitney test or Wilcoxon 
matched-pairs signed ranked test (GraphPad Prism 6) and differences were considered 
statistically significant at p < 0.05. Unless otherwise specified, results are expressed as mean ± 
standard error of the mean. FACS data were analyzed using Summit v4.3 software. 
3.6.8  Ethical considerations 
Ethical clearance was obtained from University of Gondar, Institutional Review Board (IRB). 
Additionally, Informed written consent was obtained from each patients and controls. To ensure 
confidentiality of participants, only codes were used and  their names were not indicated. 
3.6.9  Data quality control measures  
Data collectors and supervisor trained on the details of the principle and procedure of the test and 
also laboratory determination was based on Standard Operating Procedures (SOP). Instrument 
calibration like FACS caliber was calibrated using standard beads, ELISA known positive and 
negative controls was used. 
3.6.10  Dissemination of plan 
The results of the study was presented to University of Gondar as a partial fulfillment for the 
master course in Immunology. Findings will also be presented in national and international 
scientific conferences and published in international journal. 
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4. Results  
For this study, 23 patients with visceral leishmaniasis, 16 test of cure (TOC), 20 and 10 for 3rd 
month and 6th month follow up respectively, a total of 69 clinically and laboratory confirmed 
leishmania patients were enrolled in this study. For purposes of comparison 10 apparently male 
healthy controls were recruited. The median age of the patients with leishmania infection and  
healthy controls were 25 and 26.5 respectively.  
All patients recruited in the study were migrant workers and male. The diagnosis of VL was 
based on positive serology (rK39, DiaMed IT Leish, DiaMed AG, Cressiers/Morat, Switzerland) 
and presence of amastigotes in spleen or bone marrow aspirates. All patients were HIV negative. 
Most of VL patients were treated with 20 mg/kg/day of SSG + 15 mg/kg/day of paramomysin 
(PM) combination for 17 days based on their clinical finding and laboratory test and Some of 
them treated with 5 mg/kg/day of Ambisom for 30 days. 
4.1 Impact of EDTA and heparin anticoagulants on the frequency of LDGs in 
the PBMCs of VL patients 
The impact of  EDTA and heparin anticoagulants on the frequency of LDGs was assessed.  The 
results show that the frequency of LDGs is significantly lower in the PBMCs isolated from  
blood collected with heparin(1.80 ± 0.77) as compared to EDTA(5.10 ± 1.91), p< 0.0001(Figure 
1) 
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Figure 1: Percentage of low density granulocytes in tubes containing EDTA and heparin. 
PBMCs were isolated by Ficoll gradient from the blood of VL patients (n = 15). Statistical 
significance was determined by Wilcoxon paired test.  
4.2 Comparison of the impact of different anticoagulants on the frequency of 
LDGs in the PBMCs of VL patients and controls 
The effect anticoagulants on the frequency of LDGs in healthy controls and VL patients was 
assessed. The results show that during active VL the frequency of LDGs was increased (5.10 ± 
1.91) as compared to healthy controls (2.47±0.72), p=0.0013 (Figure 2a,b). In addition, in 
controls the  frequency of LDGs was higher in blood samples collected in EDTA tube than 
samples collected in heparin tubes (2.47±0.72 Vs 0.4±0.16, p=0.0020), respectively (Figures 2b, 
2c). Therefore suggesting that heparin affects the frequency of LDGs not only in active VL but 
also in controls. 
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b)                                                                  c) 
 
 
                                                                 
   
 
 
 
 
 
 
Figure 2 :- Percentages of low density granulocytes in VL patients and controls. PBMCs were 
isolated by density gradient from the blood of VL patients (n = 23) and controls (n = 10). Each 
symbol represents the value for an individual. The bars represent the median values for the 
groups and statistical significance was determined by Mann-Whitney (Figures 2a and b) and 
Wilcoxon paired tests (Figure 2c). 
4.3 The effect of EDTA and Heparin on Arginase Activity  
The results presented in Figures 1 and 2 show that the frequency of LDGs is lower when  blood 
is collected with tubes containing of heparin anticoagulant  compared to EDTA. The effect of 
using EDTA or heparin as anticoagulant in the release of arginase in the microenvironment by 
neutrophil was assessed since arginase is released by the azurophilic granules in neutrophils.  
Accordingly,  arginase activity was measured in the supernatant of stimulated cells. It has been  
found out that the levels of arginase activity difference in the whole blood assay stimulated with 
specific leishmania antigen (SLA), polyclonal stimulation with PHA and unstimulated (nil) 
samples (figure 3) did not show any difference between blood samples collected using tubes 
containing of heparin or EDTA as anticoagulant. Suggesting that the levels of arginase activity 
were not significantly affected by the different anticoagulant used (Table 1). 
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Table 1:- Arginase Activity  in the supernatant of stimulated cells with P- value 
 median±SEM 
(Heparin) 
median±SEM 
(EDTA) 
P value 
 SLA 28.10±5.171 19.85±5.807 0.9102 
 PHA 32.90±6.165 22.65±11.72 0.4316 
NIL 24.20±7.932 26.90±5.246 0.8457 
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Figure 3 :- Arginase activity in plasma (supernatant). Blood from VL patients (n=10) collected 
with heparin (H=10) and EDTA (E=10) was activated with SLA, PHA and nil. After 24 hours, 
the supernatant was harvest and arginase activity was measured by enzymatc assay. Statistical 
significance was determined by Wilcoxon paired test.  
4.4 Impact of anticoagulants on IFN-γ production in the whole blood assay 
The effect of use of EDTA and heparin anticoagulants on the levels of antigen-specific and 
polyclonal production of IFN-γ in the WBA was assessed. 
 No statistical difference was observed in the level of IFN-γ production between blood samples 
collected in EDTA and heparin tubes following stimulation with specific antigen for leishmania 
(0.0 ± 4.9 Vs. 0.0 ± 16.3, p=0.3125 respectively ) (figure 4a) and PHA (5.0 ± 18.54 Vs. 0.0±7.4, 
p=0.6523, respectively)(figure 4b). Shows that IFN-γ production was low or below detection 
limit in the WBA and that this is unlikely to be due to arginase-induced L-arginine depletion. 
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Figure 4:- IFN- levels in the supernatant of whole blood assay. (A) Comparison of SLA-
stimulated IFN-γ release in pg/ml (unstimulated value subtracted) for VL patients with EDTA 
and heparin. (B) Comparison of PHA-stimulated IFN-γ release in pg/ml (unstimulated value 
subtracted) for VL patients with EDTA and heparin. Each symbol represents the value for one 
individual. Statistical significance was determined by Wilcoxon paired test.  
 
To exclude any technical problem with the assay, the same analysis was done on samples 
collected from controls. IFN-γ was clearly detectable and Statistical difference was found in 
response to polyclonal activation, when the blood was collected with heparin, but not EDTA 
(630.4±166.1, 13.3±20.0, p=0.0020, Figure 5a). As expected, IFN-γ was low or below detection 
limit in the supernatant of whole blood from controls activated with SLA (2.10 ±1.19 pg/ml, data 
not illustrated).  
Results (Figure 5b) show that collecting blood on EDTA prevents the production of IFN-γ, 
p=0.7969. 
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Figure 5 :- IFN-γ levels in the supernatant after stimulation of PHA in whole-blood assay. 
Comparison of PHA-stimulated IFN-γ release (unstimulated value subtracted) for controls in 
EDTA and heparin. Statistical significance was determined by Wilcoxen paired test.  
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b) c) 
 
 
  
 
 
 
 
 
Figure 5 :- IFN-γ levels in plasma after stimulation of PHA in whole-blood assay. Comparison 
of PHA-stimulated IFN-γ release (unstimulated value subtracted) for VL and controls in EDTA 
and heparin. Each dot represents the value for an individual. The bars represent the median 
values for the groups. Statistical significance was determined by Mann-Whitney test. 
4.5 Production of IFN-γ in active VL and after treatment 
The level of IFN-γ production after successful treatment on test of cure (TOC), 3rd month and 6th 
month follow up patients were assessed. The results show that the production of IFN-γ with 
stimulation of SLA on TOC (824.6±541.1), 3
rd
 month (624.7±557.3) and 6
th
 month 
(2040±2145)(Figure 6a) were increased significantly and gradually after successful treatment. 
Similar results was found on stimulation of PHA on TOC (139.8±164.4), 3
rd
 month 
(798.1±215.2) and 6
th
 month (996.9±943.1) (Figure 6b). 
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Figure 6:- IFN- levels in the supernatant of whole blood assay. (a) Comparison of SLA-
stimulated IFN-γ release (unstimulated value subtracted) for different subject groups (b) 
Comparison of PHA -stimulated IFN-γ release (unstimulated value subtracted) for different 
subject groups. Each symbol represents the value for an individual. The bars represent the 
median values for the groups. Statistically significantly different median values for the groups 
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are indicated by bars and asterisks (*, p=0.0102; ***, p=0.0001,****, p < 0.0001; ns, not 
significant). 
4.6 IL-10 production in active VL and after treatment 
The production of IL-10 in the supernatant of whole blood samples stimulated with SLA were 
assessed. No statistical difference was observed in the level of IL-10 production in the 
supernatant of whole blood samples stimulated with SLA between active VL, TOC 
(10.35±15.32), 3
rd
 month (10.90±11.96) and 6
th
 month (41.15±11.82) follow up (figure 7a). 
Suggesting that, antigen-specific IL-10 levels were low or below detection limit during active 
VL and after successful treatment. 
The same analysis was done in the supernatant of whole blood samples stimulated with PHA. 
statistical difference was observed between active VL, TOC (136.4±46.59), 3
rd
 month 
(215.1±45.75) and 6
th
 month (749.2±106.8) follow up, p<0.0001 (figure 7b). shows gradually 
increasing levels of IL-10 after successful treatment 
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Figure 7:- IL-10 levels in plasma after stimulation with SLA and PHA in whole-blood assay. 
(a) Comparison of SLA-stimulated IL-10 release (unstimulated value subtracted) for different 
subject groups (b) Comparison of PHA -stimulated IL-10 release (unstimulated value subtracted) 
for different subject groups. Each symbol represents the value for an individual. The bars 
represent the median values for the groups. Statistically significantly different median values for 
the groups are indicated by bars and asterisks ( ****, p < 0.0001; ns, not significant). 
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5. Discussion  
Recently, the whole blood assay challenged the existing dogma on T cell hyporesponsivness 
during active VL by showing that VL patients from India maintain the capacity to produce IFN-
γ; these studies suggest that the inability of these patients to control the disease was not due to a 
defect in Th1 response. Indeed, the preliminary data suggested that the use of heparin, the 
anticoagulant used in the WBA discussed above, results in a sharp reduction on the frequency of 
LDGs.   
Results show that the frequency of LDGs is drastically reduced when the blood is collected with 
heparin, suggesting that the use of heparin as anticoagulant could result in underestimated 
frequencies of LDGs. Whereas EDTA has been shown to impact on neutrophils biological 
functions, the viability of neutrophils does not seem to be affected by different anticoagulants 
(37). 
EthyleneDiamineTetraAcetic Acid (EDTA) chelates the free calcium needed as cofactors to 
activate the enzymes responsible for coagulation, whereas heparin blocks coagulation by 
activating antithrombin (37). LDGs are a distinct subpopulation of highly activated neutrophils 
and with a very short half-life in vitro ( unpublished data). It is possible that LDGs isolated from 
blood harvested on EDTA lacks Ca
+
 required to undergo cell death and therefore survive longer 
in EDTA.  
Release of arginase in the microenvironment results in the depletion of extracellular L-arginine, 
that in turn prevent T cell activation (50,51). Results have shown that in patients with active VL, 
the frequency of activated LDGs in PBMCs is significantly increased, that these cells express 
significantly less intracellular arginase and that the levels of arginase in the plasma is 
significantly increased (38).  
The hypothesis was that the lack of IFN-γ response in the WBA could be due to increased 
released of arginase: however, the present study shows that the levels of arginase activities are 
similar in all plasma harvested 24 hours after activation of whole blood cells and therefore is 
unlikely to explain the hyporesponsiveness of the cells.  However, additional results in this study 
shows that: 
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Cells from whole blood collected on EDTA  produce low or no IFN-γ, this is likely to be due to 
the calcium chelating by EDTA. since Ca
2+
 ion is important for signaling pathway, cell division, 
proliferation and differentiation to effector T cell. as a result, this will restrict calcium-dependent 
activation responses (52,53). 
Cells from whole blood collected from patients with active VL produce low or no IFN-γ in 
response to antigen or polyclonal activations, suggesting that blood cells from active VL patients 
are hyporesponsive.  In this study any technical problems were excluded due to the assay that 
IFN-γ was clearly detectable the supernatant of whole blood cells from healthy controls activated 
with PHA.   
This results are in agreement with an evidence from the literature showing that one of the key    
immunological characteristics of active VL is a profound immunosuppression, as demonstrated 
by the failure of PBMCs to produce IFN-γ and proliferate in response to Leishmania antigen 
(reviewed in (39,40)).  
However, the results in this study are in apparent contradiction with recent studies showing that 
IFN-γ is produced by whole blood cells from active VL patients and was similar to those levels 
detected in cured patients (41,45,54). 
Furthermore, the results in this study also shows high IL-10 is not associated with active VL, nor 
that it is produced at high levels by cells from cured patients.  In addition, these results show that 
cells from active VL patients are hyporesponsive, as activation with PHA results in significant 
increased of IL-10 only in cured patients after successful treatment. 
   
Taken together, the cytokine results show that blood cells from VL patients are hyporesponsive 
to both antigen-specific and polyclonal activation. The discrepancies between the results 
presented here and the studies by (45) and (55) might be explained by several factors: 
The severity of the disease might be more acute in VL patients admitted to Gondar university 
hospital; clinical data such as BMI, anemia, co-infections, age have not been compared in this 
respective studies in Bihar and in Gondar.   
There might be genetic variation between the parasites. Indeed, there is an increased resistance of 
L. donovani to SSG in India, but not in Ethiopia (56).  
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On the other hand, patients in India respond successfully to treatment with one single dose 
AmBisome®, but a similar clinical trial had to be terminated because of low efficacy of the drug 
in Gondar (57).  
Despite the fact that it has been found little or no production of IFN-γ and IL-10 in the plasma of 
the WBA at time of acute disease, these cytokines have been clearly detected in the plasma of 
these patients directly ex vivo (summarised in (39)). demonstrating that these cytokines are been 
produced in vivo.   
Indeed, whereas the levels of these cytokines in the WBA in response to antigenic or polyclonal 
activation was below or barely above the levels of cytokines detected in the absence of 
stimulation, IFN-γ and IL-10 were detectable in the supernatant of the unstimulated whole blood 
cells (185.9±178.7 and 61.5±12.6 ng/ml, respectively) as well as in the plasma of these patients 
(123.0±27.5 and 88.9±12.5 ng/ml, respectively) (data not illustrated). 
This demonstrate that this cytokines are produced in vivo, but cannot be induced to be produced 
in vitro in response to activation.  It is tempted to speculate that other cells, such as neutrophils 
and monocytes produce these cytokines (39).  
 
In the current study, results show that whole blood cells from active VL patients are 
hyporesponsive as no or low IFN-γ was induced in response to activation. Since a recent study 
showed that IFN-γ produced by antigen-specific CD4+ T cells contributes to the control of 
parasite replication in VL patients, it is possible that the lack of appropriate Th1 response might 
be responsible for the uncontrolled replication of parasite in the patients that are recruited in 
Gondar (54).  
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6. Conclusion and recommendations 
Heparin is a well known anticoagulant and causes a dramatic decrease on the frequency of 
LDGs. EDTA has an effect on the production of IFN-γ. The levels of arginase activity are not 
significantly affected by the different anticoagulant used. Active VL patients are hyporesponsive 
and that high IL-10 is not associated with active VL. As a result, choosing different 
anticoagulants to study about different cells and T cell response against leishmania is important 
for the future in vitro experiment and also to avoid ambiguous results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
29 
 
7. Limitation 
Demographic data and clinical finding such as age, anemia, BMI and duration of illness were not 
compared with the Indian study. 
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Annex:  
Annex: I    Consent Form 
Title of the Study:- The effect of EDTA and Heparin anticoagulants on the 
survival of  Neutrophils and T-cell responses among Visceral Leishmaniasis 
Patients in North West Ethiopia 
I am a student at University of Gondar and planning to assess the impact of Heparin and EDTA  
anticoagulant on the survival of neutrophils and the release of interferon-γ and IL-10  in North 
West Ethiopia. I believe that this study is important to give a valuable information about the effect 
of anticoagulant on neutrophil and the release of  interferon-γ and IL-10. This would help  future 
in vitro experiment for researchers to use the correct anticoagulant type while studying T-cell 
response against leishmania. You/your child are confirmed to have this disease and If you wish to 
participate in this study you will be asked to give 8ml blood sample and I will use some of the 
information on your hospital chart, There is no additional risk incurred to you due to your 
participation in this study. Your participation to this study should be fully voluntary and you have 
the right to withdraw from the study at any time during the study. You will not get any additional 
benefits or compensations by participating in this study except for transportation re-imbursement. 
The findings of this study will help to have a good information about the anticoagulant effect. We 
assure you that any information collected from you for the purpose of the study will be kept 
confidential at all times. 
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For participation into the study 
I, the undersigned, would like to confirm that, in giving my consent to participate in the study, it 
is with a clear understanding of the objectives and conditions of the study and with the 
recognition of my right to resign from the study.  
I …….…………………do hereby give consent to Mr./Ms. _____________________to include 
me in the proposed research to test the blood. I have been given the necessary information to 
understand that it will be necessary to collect the blood and that there are no additional risks 
involved in donating the samples and participating in this research. I have been assured that I can 
withdraw my consent at any time without penalty or a loss of benefit. The proposal has been 
explained to me in the language I am fluent and conversant. 
 
Patient 
Print Name:  Date:  
     Sign Name: 
 Time:  
Person Conducting the Informed Consent 
Print Name:  Date:  
Sign Name:  Time:  
Witness 
Print Name:  Date:  
Sign Name:  Time:  
 
Contact person: 
 
Name:    _______________________________________________________________ 
Address: _____________________________________________________________ 
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Consent form Amharic version  
የጥናቱ ርዕስ : በካላዛር በሽተኞች ላይ የዯም ናሙና በመጠቀመም 
በላብራቶሪ ውስጥ ዯም እንዲይረጋ የሚያዯርጉት ንጥረ-ነገሮች በነጭ የዯም 
ተህዋስያን ላይ የሚያዯርሱት የጎንዮሽ ጉዲት ላይ የሚዯረግ ጥናት በሰሜን 
ምእራብ ኢትዮጵያ፡፡ 
እኔ የጎንዯር ዩኒቨርሲቲ ተማሪ ስሆን በሰሜን ምእራብ ኢትዩጵያ ዉስጥ በሚገኙ የካላዛር 
በሽተኞች ላይ ጥናት ማድረግ እፈልጋሇሁ፡፡ጥናቴም የሚያተኩረው በላብራቶሪ ውስጥ ዯም 
እንዲይረጋ የሚያዯርጉት ንጥረ-ነገሮች ማሇትም ሄፓሪን እና ኢዱቲኤ በነጭ የዯም 
ተህዋስያን እና በሽታውን ሇመከላከል ከሚሇቀቁት ንጥረ-ነገሮች የሚያዯርሱት ጉዲት ላይ 
ነው፡፡እናም ይህ ጥናት ዯም እንዲይረጋ በሚያዯርጉት ንጥረ-ነገሮች ላይ ጥሩ እውቀት 
እንዱኖረን ያዯርጋል የሚል እምነት አሇኝ፡፡ እንዱሁም ሇወዯፊት ተመራማረዎች 
ትክክሇኛውን ንጥረ-ነገር በመጠቀም ሇበሽታው የሚያዯረግ የመከላከል አቅምን ሇማወቅ 
ይረዲል፡፡በመሆኑም እርስዎ/ልጅዎ ላይ ይህ በሽታ እንዲሇ ተረጋግጧል፡፡ በዚህ ጥናት ላይ 
ሇመሳተፍ ከፈቀደ የዯም ናሙና እንዱሰጡ ይጠየቃለ እንዱሁም ከሆስፒታል መዝገብዎ 
ላይ የተመዘገቡ አንዲንድ መረጃዎችን ሇጥናቱ እንጠቀማሇን እናም የሰጡትን የዯም 
ናሙና በመጠቀም የምርምር ስራዉን የምናከናዉን ይሆናል፡፡በዚህ ጥናት ላይ በመሳተፍዎ 
የሚዯርስብዎ ምንም አይነት ጉዲት የሇም፡፡ በዚህ ጥናት ላይ ሲሳተፉ በሙለ ፈቃዯኝነት 
መሆን ይኖርበታል፤ እንዱሁም በጥናቱ ላይ ሲሳተፉ በማንኛዉም ሰዓት ከጥናቱ የማቋረጥ 
መብትዎ ሙለ በሙለ የተጠበቀ ነዉ፡፡ በዚህ ጥናት በመሳተፍ የሚያገኙት የተሇየ 
ጥቅማጥቅም አይኖርም፤ ነገር ግን የዚህ ጥናት ዉጤት ሇወዯፊት ዯም እንዲይረጋ 
በሚያዯርጉት ንጥረ-ነገሮች ላይ ጥሩ እውቀት እንዱኖረን ያዯርጋል፡፡ ሇዚህ ጥናት 
አገልግሎት የተሰበሰቡ እርስዎን የተመሇከቱ መረጃዎች በሙለ በማንኛዉም ጊዜ 
በሚስጥር የሚያዙ መሆኑን እናረጋግጥልዎታሇን፡፡ 
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ስምምነት ማረጋገጫ   
ጥናት ላይ ሇመሳተፍ 
ስሇጥናቱ የተሰጠኝን ማብራሪያ በበቂ ሁኔታ በመረዲት በጥናቱ ላይ ሇመሳተፍ 
ፈቃዯኛነቴን እየገሇጽኩ፤ በማንኛዉም ሰዓት ከጥናቱ እራሴን የማግሇል መብት እንዲሇኝም 
ተረድቻሇሁ፡፡ 
እኔ _______________ ከዚህ በታች የፈረምኩት ሇአቶ/ወሪት/ወ/ሮ/ ______________ 
በጥናቱ ላይ እንዱያሳትፉኝ እና  የዯም ናሙና ወስዯዉ እንዱመረምሩ ፈቅጃሇሁ፡፡ 
ከጥናቱ የማቋረጥ መብቴ መሆኑን፤ ከጥናቱ ማቋረጤ ከሚዯረግልኝ ህክምና የማያስከሇክሇኝ 
መሆኑ፤ እንዱሁም ስሇጥናቱ አላማ በአፍ መፍቻ ቋንቋየ ተብራርቶልኛል፡፡ 
ፈቃዯ˜ነት ¾ሰጠዉ 
ስም  ቀን  
ፊርማ  ሰዓት  
ፈቃዯንነታቸዉን የተቀበሇዉ  
ስም  ቀን  
ፊርማ  ሰዓት  
የምስክር 
ስም  ቀን  
ፊርማ  ሰዓት  
 
ጥናቱን የሚያካሂዯዉ ሰዉ አድራሻ 
 
ስም: _______________________________________________________________ 
 
አድራሻ: _____________________________________________________________ 
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Annex: II   Information Sheet 
 Case Report Form (CRF) 
Demographic Information 
 
1. Code                                                        VL -  
2. Chart No.                                                   _______________ 
3.   Sex                                                                        Male            Female 
4.  Age                           ______Years 
5.  Height                                                           _______ Meter 
6.  Weight                                                           ________ Kilo Gram 
7.  BMI                              ___________ 
8.  Duration of illness                                          ____________ 
9.  Parasitic Load                                                Spleen   ___________ 
                                                                             Bone Marrow  _________ 
10. Complete Blood Count 
                 - WBC   ___________                              -  MCH _____________ 
                -  HGB    ___________                   -  MCHC  ___________ 
                 - HCT   ____________                   -  Granulocyte ________ 
                -  Lymph ___________                    - Neutrophil _________ 
                 - RBC   ____________                             - MCV 
                 - PLT   ____________ 
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   11. GOT   ___________ 
   12. GPT   ___________ 
   13. Spleen Size _______ 
   14. Liver Size ________ 
   15. Upper arm Circumference _________ 
   15. Place of Residence ______________ 
   16. Date of Starting Treatment __________ 
   17. End of Treatment ______________     
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Annex: III   Laboratory procedures 
I. Procedure for PBMCs isolation for EDTA and Heparin 
1. Pipette 4ml Ficoll Histopaque 1077 into a 4ml centrifuge tube 
2. Slowly pipette 4ml blood on top of Ficoll (slant tube when dispensing blood) 
3. Centrifuge at 1900rpm with no brake for 30 minutes at room temp. 
4. Using a sterile pipette collect the interphase  below the plasma (PBMC) (collecting as little 
Ficoll as possible) 
5. Wash the interphase with PBS (fill centrifuge tube) 
6. Centrifuge 1800rpm for 5 minutes at room temp. 
7. Pour away the supernatant and dilute the sediment with 2ml of PBS. 
8. Use the PBMCs for FACS  analysis by adding monoclonal antibody (anti-CD15 and anti-
Arginase) 
 
II. Procedure for arginase assay 
1. Defrost samples 
2. Vortex defrosted sample and centrifuge 10 min 2300rpm 
3. Label 1.5ml eppendrof tubes 
4. Pipette 25l of samples in all the tubes 
5. Pipette 25l of lysis buffer to each sample  
6. Vortex (can leave at 4C if necessary, vortex before use) 
7. Using a thermal cycler, incubate at 56C for 7 minutes this activates the arginase present in 
the sample. 
8. Take an aliquot of L-arginine (0.5M at pH9.7) from the freezer, thaw  
9.  Pipette 50ul L-arginine into each tub. 
10.   Vortex  
11.   Using the same thermal cycler, incubate at 37C for 120 minutes.  
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12.   Pipette and add 400ul acid mixture to stop the reaction (wear lab coat, gloves and   
GOGGLES!) (Can leave at 4C if necessary) 
13.   In 6 new 0.5ml eppendorfs, pipette London water and urea standard: 
     Table -4 :- Urea standard preparation. 
Tube number  London Water (l) Urea Volume (l) Urea Conc. (g) 
1 50 50 60 
2 75 25 30 
3 87.5 12.5 15 
4 93.8 6.2 7.5 
5 96.9 3.1 3.75 
6 98.4 1.6 1.88 
 
14.   Pipette and add 400l acid mixture to the urea standards (GOGGLES!!!!) (Can leave at 4C 
if necessary) 
15.   Pipette 20ul 6% ISPF to ALL sample and standard tubes. 
16.  VORTEX TUBES EXTREMELY WELL until the phases are mixed – this is EXTREMELY 
IMPORTANT!!!! 
17.  Using the same thermal cycler, incubate all samples and standards at 99C for 45minutes 
using a weight on top of the tubes. 
18.  Incubate a further 30minutes at 4oC 
19. When the urea reacts with the coloring agent ISPF it produces a pink to purple color. 
20.  Pipette 200l of urea standard and the samples onto a 96 flat bottom well plate (non-sterile 
plate) 
21.  Read the absorbance of both the standard and the sample at 540nm 
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Calculation 
Arginase Activity 
g urea x dilution x homogenate volume x mU 
M urea(60g)  x time in minutes x homogenate fraction volume 
 = mU/ml 
 
III. ELISA procedure for IFN-γ and IL-10 
1.  Coat Corning Costar 9018 (or Nunc Maxisorp®) ELISA plate with 100 µL/well of capture  
antibody in 1X Coating Buffer (dilute as noted on C of A, which is included with the reagent  
set). Seal the plate and incubate overnight at 4°C.   
2.  Aspirate wells and wash 3 times with >250 µL/well Wash Buffer*.  Allowing time for 
soaking (~ 1 minute) during each wash step increases the effectiveness of the washes. Blot plate 
on absorbent paper to remove any residual buffer.   
3.  Dilute 1 part 5X ELISA/ELISPOT Diluent with 4 parts DI water.* Block wells with 200 
µL/well of 1X ELISA/ELISPOT Diluent. Incubate at room temperature for 1 hour.   
4.  Optional: Aspirate and wash at least once with Wash Buffer.   
5.  Using DI water, reconstitute lyophilized standards as noted on the C of A. Allow to sit for 15 
minutes with gentle agitation prior to diluting further 
6.  Using 1X ELISA/ELISPOT Diluent*, dilute the reconstituted standard as noted on the C of A 
to prepare the top standard concentration. Add 100 µL/well of top standard concentration to the 
appropriate wells. Perform 2-fold serial dilutions of the top standards to make the standard curve 
for a total of 8 points. Add 100 µL/well of your samples to the appropriate wells.  Include at least 
two wells with 100 µL/well of 1X ELISA/ELISPOT Diluent only to serve as plate blanks. Seal 
the plate and incubate at room temperature for 2 hours (or overnight at 4°C for maximal 
sensitivity).   
7.  Aspirate/wash as in step 2. Repeat for a total of 3-5 washes**.   
8.  Add 100 µL/well of detection antibody diluted in 1X ELISA/ELISPOT Diluent * (dilute as 
noted on C of A). Seal the plate and incubate at room temperature for 1 hour.   
9.  Aspirate/wash as in step 2. Repeat for a total of 3-5 washes**.   
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10.  Add 100 µL/well of Avidin-HRP* diluted in 1X ELISA/ELISPOT Diluent  (dilute as noted 
on C of A). Seal the plate and incubate at room temperature for 30 minutes.  
11.  Aspirate and wash as in step 2. In this wash step, soak wells in Wash Buffer* for 1 to 2 
minutes prior to aspiration. Repeat for a total of 5-7 washes**.   
12.  Add 100 µL/well of 1X TMB Solution to each well. Incubate plate at room temperature for 
15 minutes.   
13.  Add 50 µL of Stop Solution to each well.   
14.  Read plate at 450 nm. If wavelength subtraction is available, subtract the values of 570 nm 
from those of 450 nm and analyze data.  
 NOTES:  * Be certain that no sodium azide is present in the solutions used in this assay, as this 
inhibits HRP enzyme activity.  
 **The number of washes in the protocol was adapted to an automatic plate washer. This can be  
decreased  when  using  other methods  but  should  be  tested  empirically. Allowing time for 
soaking (~1 minute) during each wash step increases the effectiveness of the washes. 
 
 
